Wuxi Biologics (Cayman) (2269N) Ratios
Wuxi Biologics (Cayman) Ratios
MX:2269N's free cash flow for Q2 2026 was $1.63B. For the 2026 fiscal year, MX:2269N's free cash flow was decreased by $-2.82B and operating cash flow was $4.46B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.14 | 2.73 | 2.78 | 1.98 | 2.37 |
| Quick Ratio | 2.97 | 2.56 | 2.54 | 1.74 | 2.16 |
| Cash Ratio | 1.11 | 0.96 | 1.27 | 0.69 | 1.09 |
| Solvency Ratio | 0.62 | 0.42 | 0.36 | 0.39 | 0.34 |
| Operating Cash Flow Ratio | 0.77 | 0.61 | 0.61 | 0.59 | 0.42 |
| Short-Term Operating Cash Flow Coverage | 7.31 | 2.14 | 8.10 | 4.19 | 1.62 |
| Net Current Asset Value | $ 15.47B | $ 12.07B | $ 8.64B | $ 5.12B | $ 8.20B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.09 | 0.08 | 0.09 | 0.10 |
| Debt-to-Equity Ratio | 0.07 | 0.12 | 0.11 | 0.13 | 0.13 |
| Debt-to-Capital Ratio | 0.06 | 0.11 | 0.10 | 0.11 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.04 | 0.04 | 0.02 |
| Financial Leverage Ratio | 1.35 | 1.36 | 1.40 | 1.41 | 1.36 |
| Debt Service Coverage Ratio | 6.76 | 2.14 | 6.67 | 3.91 | 1.86 |
| Interest Coverage Ratio | 47.65 | 31.56 | 28.08 | 67.44 | 81.35 |
| Debt to Market Cap | 0.01 | 0.04 | 0.02 | 0.01 | 0.01 |
| Interest Debt Per Share | 0.78 | 1.25 | 1.13 | 1.08 | 0.98 |
| Net Debt to EBITDA | -0.73 | -0.52 | -0.93 | -0.32 | -1.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 45.98% | 40.97% | 40.08% | 44.04% | 46.93% |
| EBIT Margin | 30.50% | 26.73% | 25.43% | 35.51% | 39.19% |
| EBITDA Margin | 38.41% | 34.43% | 32.30% | 40.76% | 43.87% |
| Operating Profit Margin | 30.47% | 26.63% | 26.12% | 28.44% | 30.98% |
| Pretax Profit Margin | 33.30% | 25.89% | 24.50% | 35.09% | 38.81% |
| Net Profit Margin | 22.53% | 17.97% | 19.96% | 28.95% | 32.93% |
| Continuous Operations Profit Margin | 26.31% | 21.13% | 20.96% | 29.80% | 34.10% |
| Net Income Per EBT | 67.64% | 69.42% | 81.45% | 82.50% | 84.86% |
| EBT Per EBIT | 109.29% | 97.20% | 93.79% | 123.40% | 125.25% |
| Return on Assets (ROA) | 7.70% | 5.89% | 6.01% | 8.92% | 7.70% |
| Return on Equity (ROE) | 10.38% | 8.03% | 8.43% | 12.61% | 10.50% |
| Return on Capital Employed (ROCE) | 11.98% | 10.29% | 9.09% | 10.79% | 8.91% |
| Return on Invested Capital (ROIC) | 9.26% | 7.96% | 7.66% | 8.84% | 7.37% |
| Return on Tangible Assets | 7.95% | 6.10% | 6.23% | 9.31% | 8.09% |
| Earnings Yield | 4.16% | 4.99% | 3.14% | 2.00% | 1.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.45 | 3.23 | 2.73 | 2.96 | 3.14 |
| Payables Turnover | 10.78 | 14.76 | 12.25 | 10.76 | 8.84 |
| Inventory Turnover | 8.17 | 7.25 | 5.78 | 3.75 | 3.24 |
| Fixed Asset Turnover | 0.73 | 0.66 | 0.57 | 0.59 | 0.52 |
| Asset Turnover | 0.34 | 0.33 | 0.30 | 0.31 | 0.23 |
| Working Capital Turnover Ratio | 1.33 | 1.31 | 1.50 | 1.50 | 0.98 |
| Cash Conversion Cycle | 159.89 | 138.74 | 167.23 | 186.81 | 187.59 |
| Days of Sales Outstanding | 149.07 | 113.10 | 133.88 | 123.31 | 116.10 |
| Days of Inventory Outstanding | 44.67 | 50.38 | 63.15 | 97.43 | 112.78 |
| Days of Payables Outstanding | 33.86 | 24.74 | 29.80 | 33.93 | 41.29 |
| Operating Cycle | 193.74 | 163.48 | 197.03 | 220.75 | 228.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.53 | 1.28 | 1.12 | 1.33 | 0.78 |
| Free Cash Flow Per Share | 0.67 | 0.32 | 0.11 | -0.08 | -0.70 |
| Dividend Paid and CapEx Coverage Ratio | 1.78 | 1.33 | 1.10 | 0.94 | 0.53 |
| Capital Expenditure Coverage Ratio | 1.78 | 1.33 | 1.10 | 0.94 | 0.53 |
| Operating Cash Flow Coverage Ratio | 2.06 | 1.06 | 1.02 | 1.25 | 0.80 |
| Operating Cash Flow to Sales Ratio | 0.29 | 0.28 | 0.27 | 0.36 | 0.33 |
| Free Cash Flow Yield | 2.37% | 1.91% | 0.40% | -0.15% | -0.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.34 | 20.06 | 31.85 | 49.89 | 97.89 |
| Price-to-Sales (P/S) Ratio | 5.41 | 3.60 | 6.36 | 14.44 | 32.23 |
| Price-to-Book (P/B) Ratio | 2.49 | 1.61 | 2.68 | 6.29 | 10.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 42.13 | 52.28 | 247.65 | -674.95 | -107.28 |
| Price-to-Operating Cash Flow Ratio | 18.46 | 12.90 | 23.20 | 39.79 | 96.67 |
| Price-to-Earnings Growth (PEG) Ratio | 0.59 | 0.00 | -1.41 | 1.62 | 1.11 |
| Enterprise Value Multiple | 13.36 | 9.95 | 18.75 | 35.12 | 72.44 |
| Enterprise Value | 111.80B | 63.98B | 103.16B | 218.55B | 326.98B |
| EV to EBITDA | 13.36 | 9.95 | 18.75 | 35.12 | 72.44 |
| EV to Sales | 5.13 | 3.43 | 6.06 | 14.31 | 31.78 |
| EV to Free Cash Flow | 39.95 | 49.69 | 235.97 | -668.91 | -105.75 |
| EV to Operating Cash Flow | 17.50 | 12.26 | 22.10 | 39.44 | 95.29 |
| Tangible Book Value Per Share | 12.23 | 10.66 | 10.08 | 8.18 | 6.95 |
| Shareholders’ Equity Per Share | 11.32 | 10.24 | 9.69 | 8.40 | 7.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.18 | 0.14 | 0.15 | 0.12 |
| Revenue Per Share | 5.22 | 4.57 | 4.09 | 3.66 | 2.34 |
| Net Income Per Share | 1.18 | 0.82 | 0.82 | 1.06 | 0.77 |
| Tax Burden | 0.68 | 0.69 | 0.81 | 0.83 | 0.85 |
| Interest Burden | 1.09 | 0.97 | 0.96 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.04 | 0.04 | 0.05 | 0.04 | 0.05 |
| SG&A to Revenue | 0.11 | 0.11 | 0.09 | 0.08 | 0.09 |
| Stock-Based Compensation to Revenue | 0.04 | 0.07 | 0.07 | 0.08 | 0.05 |
| Income Quality | 1.30 | 1.08 | 1.37 | 1.25 | 0.86 |
Currency in CNY
